← Leaderboards
Timothy J. Collier
Rush University Medical Center
$11,066,916
Attributed
$12,307,250
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$18,226,606 · 10
By mechanism
R01$8,566,185 · 4
P50$7,744,007 · 3
P01$1,471,039 · 1
R21$430,375 · 1
R13$15,000 · 1
Top collaborators
- Jeffrey H Kordower5 shared
- Thyagarajan Subramanian1 shared
Most similar at Rush University Medical Center
Same institution · by research overlap
- Caryl E Sortwell$6,394,251
Others in their field
Top investigators on “Dopamine”
- Pedro A. Jose · George Washington University$34,248,029
- Jonathan A Javitch · Columbia University Health Sciences$28,566,988
- Michael A Nader · Emory University$26,344,520
- Dalton James Surmeier · University Of Tennessee Health Sci Ctr$23,527,588
- Michael A Schwarzschild · Massachusetts General Hospital$22,973,787
- David Sulzer · Columbia University Health Sciences$22,837,505
Research focus
DopamineParkinson DiseaseRattusNeuronsApoptosisStructureDopaminergic NeuronCellsTransplantationBasal GangliaPhenotypeRecoveryResearch StudyBehavioralTherapeutic EffectOxidative StressMorphologyProgenitorIn VivoIn VitroCorpus Striatum StructureEmbryo /Fetus Tissue TransplantationMediatingTyrosine 3-Monooxygenase
Grant awards (44)
Circadian disruption as an accelerator of synucleinopathy$430,375
R21 · FY2022 · NS · contact PI
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease$432,538
R01 · FY2019 · NS · contact PI
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease$410,256
R01 · FY2018 · NS · contact PI
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease$557,329
R01 · FY2017 · NS · contact PI
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease$576,131
R01 · FY2016 · NS · contact PI
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease$489,414
R01 · FY2015 · NS · contact PI
Aging and Parkinson's Disease: Models of Therapeutics and Neurologic Comorbidity$2,500
P50 · FY2015 · NS · contact PI
Aging and Parkinson's Disease: Models of Therapeutics and Neurologic Comorbidity$2,500
P50 · FY2014 · NS · contact PI
Aging and Parkinson's Disease: Models of Therapeutics and Neurologic Comorbidity$1,093,530
P50 · FY2013 · NS · contact PI
Induction of dopamine system plasticity by grafted undifferentiated neural progen$252,737
P50 · FY2013 · NS · contact PI
Adminstrative Core$121,878
P50 · FY2013 · NS · contact PI
Aging and Parkinson's Disease: Models of Therapeutics and Neurologic Comorbidity$1,142,463
P50 · FY2012 · NS · contact PI
Induction of dopamine system plasticity by grafted undifferentiated neural progen$293,762
P50 · FY2012 · NS · contact PI
Adminstrative Core$84,375
P50 · FY2012 · NS · contact PI
Aging and Parkinson's Disease: Models of Therapeutics and Neurologic Comorbidity$1,197,836
P50 · FY2011 · NS · contact PI
An Approach to Dopamine Graft Augmentation$325,850
R01 · FY2011 · NS · contact PI
Induction of dopamine system plasticity by grafted undifferentiated neural progen$269,054
P50 · FY2011 · NS · contact PI
Adminstrative Core$85,789
P50 · FY2011 · NS · contact PI
Aging and Parkinson's Disease: Models of Therapeutics and Neurologic Comorbidity$1,201,267
P50 · FY2010 · NS · contact PI
Induction of dopamine system plasticity by grafted undifferentiated neural progen$271,238
P50 · FY2010 · NS · contact PI
An Approach to Dopamine Graft Augmentation$237,130
R01 · FY2010 · NS · contact PI
An Approach to Dopamine Graft Augmentation$94,311
R01 · FY2010 · NS · contact PI
Adminstrative Core$77,249
P50 · FY2010 · NS · contact PI
Aging and Parkinson's Disease: Models of Therapeutics and Neurologic Comorbidity$1,279,260
P50 · FY2009 · NS · contact PI
An Approach to Dopamine Graft Augmentation$341,250
R01 · FY2009 · NS · contact PI
Induction of dopamine system plasticity by grafted undifferentiated neural progen$275,675
P50 · FY2009 · NS · contact PI
Adminstrative Core$92,894
P50 · FY2009 · NS · contact PI
An Approach to Dopamine Graft Augmentation$341,250
R01 · FY2008 · NS · contact PI
ASNTR Annual Meeting Student Travel Awards$15,000
R13 · FY2008 · NS
An Approach to Dopamine Graft Augmentation$341,250
R01 · FY2007 · NS · contact PI
Increasing dopamine neuron survival during grafting$279,657
P01 · FY2007 · NS · contact PI
Increasing dopamine neuron survival during grafting$294,939
P01 · FY2006 · NS · contact PI
Increasing dopamine neuron survival during grafting$294,939
P01 · FY2005 · NS
Cell Grafts for Parkinson's Disease$362,500
R01 · FY2004 · NS
Increasing dopamine neuron survival during grafting$294,939
P01 · FY2004 · NS
AGING AND DOPAMINE GRAFTS IN PARKINSONIAN MONKEYS$692,023
R01 · FY2003 · AG
Cell Grafts for Parkinson's Disease$362,500
R01 · FY2003 · NS
Increasing dopamine neuron survival during grafting$306,565
P01 · FY2003 · NS
AGING AND DOPAMINE GRAFTS IN PARKINSONIAN MONKEYS$106,220
R01 · FY2003 · AG
AGING AND DOPAMINE GRAFTS IN PARKINSONIAN MONKEYS$712,780
R01 · FY2002 · AG
Cell Grafts for Parkinson's Disease$362,500
R01 · FY2002 · NS
AGING AND DOPAMINE GRAFTS IN PARKINSONIAN MONKEYS$728,971
R01 · FY2001 · AG
Cell Grafts for Parkinson's Disease$358,900
R01 · FY2001 · NS
AGING AND DOPAMINE GRAFTS IN PARKINSONIAN MONKEYS$733,082
R01 · FY2000 · AG